SD 1 tm2117943-1_sd.htm SD

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  

FORM SD

SPECIALIZED DISCLOSURE REPORT

  

Itamar Medical Ltd.

(Exact name of Registrant as Specified in its Charter)

  

Israel   001-38755   n/a

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

9 Halamish Street, Caesarea 3079883, Israel   n/a
(Address of principal executive offices)   (Zip Code)

 

Noa Farkas Gluck, General Counsel   +972-4-6177000

(Name and telephone number, including area code, of the person to contact in connection with this report.)

  

Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

 

xRule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2020.

 

 

 

 

 

INFORMATION TO BE INCLUDED IN THE REPORT

 

Section 1 - Conflict Minerals Disclosure

 

Item 1.01 Conflict Minerals Disclosure and Report

 

In accordance with Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended (the “Rule”), which was adopted by the United States Securities and Exchange Commission (“SEC”) to implement reporting and disclosure related to “conflict minerals”, including tin, tantalum, tungsten and gold (“Conflict Minerals” or “3TG”), originating in the Democratic Republic of the Congo (“DRC”) or an adjoining country (collectively referred to as the “Covered Countries”), Itamar Medical Ltd. (the “Company,” “Itamar Medical,“ “we,“ or “us”) has evaluated its current products and determined that, although the Company does not directly purchase minerals from smelters or other minerals within the supply chain, certain parts of the products that the company manufactured or contracted to manufacture in the year ended December 31, 2020 may have contained necessary Conflict Minerals. In connection with the Rule, the Company has adopted a Conflict Minerals Policy with respect to the responsible sourcing of conflict minerals. Accordingly, the Company is filing this disclosure along with a Conflict Minerals Report to disclose the measures it has taken to determine the origin, or likely origin, of the Conflict Minerals used in our products.

 

Conflict Minerals Disclosure

 

A copy of the Company’s Conflict Minerals Report is provided as Exhibit 1.01 hereto and details the due diligence measures undertaken during the reporting period by the Company. A copy of the Conflict Minerals Report is also publicly available through the Company’s website:  https://www.itamar-medical.com/social-responsibility/

 

Item 1.02 Exhibit

 

The Company has filed, as exhibits to this Form SD, the Conflict Minerals Report of the Company required by Item 1.01.

 

Section 2 - Exhibits

 

Item 2.01 Exhibits

 

The following exhibit is filed as part of this report:

 

Exhibit 1.01 Conflict Minerals Report of the Company

 

 

 

 

SIGNATURES

  

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    ITAMAR MEDICAL LTD.  
       
       
  By: /s/ Dan Shlezak  
    Dan Shlezak,  
    General Manager, Israel  

 

Date: May 28, 2021